A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment.
D B Clifford, J C McArthur, G Schifitto...
https://pubmed.ncbi.nlm.nih.gov/12451199/Status Unknown
Led by Centaur Pharmaceuticals · Updated on 2005-06-24
60
Participants Needed
6
Research Sites
N/A
Total Duration
The purpose of this study is to see if it is safe and effective to give CPI-1189 to patients with AIDS dementia. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to loss of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.
CONDITIONS
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Centaur Pharmaceuticals
Lead Sponsor
Inclusion Criteria
You may be eligible for this study if you:
Exclusion Criteria
You will not be eligible for this study if you:
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
D B Clifford, J C McArthur, G Schifitto...
https://pubmed.ncbi.nlm.nih.gov/12451199/Centaur Pharmaceuticals
Lead Sponsor